Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 5, 2007, Pages 575-580

  Niioka, Takenori ^a   Uno, Tsukasa ^a,b   Yasui Furukori, Norio ^b   Takahata, Takenori ^b   Shimizu, Mikiko ^b   Sugawara, Kazunobu ^a   Tateishi, Tomonori ^b  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

AUC; Low dose; Nedaplatin; Pharmacokinetics; Predictability; Therapeutic drug monitoring

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; NEDAPLATIN; PACLITAXEL; RANITIDINE;

ACCURACY; ADULT; AGED; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY REACTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY SURFACE AREA; CARCINOMA, NON-SMALL-CELL LUNG; DATA INTERPRETATION, STATISTICAL; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 33847140490     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0298-2     Document Type: Article

References (20)

1. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
2. Chatelut E, Canal P, Brunner V, Chevreau C, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580
3. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
4. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733-3739
5. Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 38:1677-1684
6. Furuse K, Fukuoka M, Kurita Y, Ariyoshi Y, Niitani H, Yoneda S, Fujii M, Hasegawa K, Nishiwaki Y, Tamura M, Kimura I, Inoue S, Oshima S, Kusume K, Sugimoto K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer (in Japanese). Jpn J Cancer Chemother 19:879-884
7. Hasegawa Y, Takanashi S, Okudera K, Aoki M, Basaki K, Kondo H, Takahata T, Yasui-Furukori N, Tateishi T, Abe Y, Okumura K (2004) Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study. Jpn J Clin Oncol 34:647-653
8. Ikeuchi I, Daikatsu K, Fujisaka I, Amano T (1990) Determination of platinum in biological materials by graphite furnace atomic absorption spectrometry (written in Japanese, only abstract is given in English). Iyakuhin Kenkyu 21:1082-1087
9. Ishibashi T, Fukumura K, Yano Y, Oguma T (2005) Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion. Anticancer Res 25:1283-1289
10. Ishibashi T, Yano Y, Oguma T (2005) Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis. Anticancer Res 25:1273-1281
11. Ishibashi T, Yano Y, Oguma T (2003) Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 56:205-213
12. Ishibashi T, Yano Y, Oguma T (2002) A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol 50:230-236
13. Koenuma M, Kasai H, Uchida N, Takeda Y, Shiratori O, Muraoka Y, Totani T (1995) Antitumor activity of a new platinum complex, nedaplatin (in Japanese). Clin Rep 29:3213-3222
14. Newell DR, Pearson ADJ, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis IJ, Pinkerton CR, Stevens MCG (1993) Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 11:2314-2323
15. Ota K (1996) Nedaplatin (in Japanese). Jpn J Cancer Chemother 23:379-387
16. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N (1991) Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 51:1472-1477
17. Sawyer M, Ratain MJ (2001) Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171-177
18. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
19. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 22:379-392
20. Weiss RB, Christian MC (1993) New cisplatin analogues in development. Drugs 46:360-377